Breaking News Bar

Business News and Information

The Daily Herald Market Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Audentes Therapeutics Inc (NQ: BOLD)
24.56 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 4:44 PM EST, Jan 18, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open -
Bid (Size) 24.56 (3)
Ask (Size) 24.57 (13)
Prev. Close 24.56
Today's Range 24.56 - 24.56
52wk Range 17.95 - 46.18
Shares Outstanding 36,743,621
Dividend Yield N/A
Performance
YTD
+10.58%
+10.58%
1 Month
+33.26%
+33.26%
3 Month
-9.04%
-9.04%
6 Month
-39.80%
-39.80%
1 Year
-34.17%
-34.17%
Top News
More News
Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities
- Completed productive initial interactions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to discuss potential registration pathways for AT132 for the... Read More
from PR Newswire
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare... Read More
from PR Newswire
More News
Read More
Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer
from PR Newswire
Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
from PR Newswire
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
from PR Newswire
Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences — Renewed Outlook, Key
from GlobeNewswire News Releases
Investors Land BOLD 18.9% Cheaper Than Its Secondary Stock Offering
category Stocks
from Market News Video
Analysts See 32% Upside For The Holdings of KOMP
category ETFs
from ETF Channel
Interesting BOLD Put And Call Options For January 2019
category Stocks
from Market News Video
Implied ESML Analyst Target Price: $31
category ETFs
from ETF Channel
These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account